Loading clinical trials...
Loading clinical trials...
A Phase I, Dose-finding Study of the Oral, Dual Phosphatidylinositol 3(PI3)-Kinase / Mammilian Target of Rapamycin (mTOR) Inhibitor BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia
Conditions
Interventions
BEZ235
Locations
1
Germany
Johann Wolfgang Goethe University Hospitals
Frankfurt am Main, Hesse, Germany
Start Date
June 1, 2012
Primary Completion Date
December 1, 2017
Completion Date
February 7, 2020
Last Updated
February 16, 2023
NCT07295951
NCT07523555
NCT05735717
NCT07223021
NCT07371403
NCT05376111
Lead Sponsor
Goethe University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions